Eight years is a long time to wait for a game to finally get ported from Japan to America. We’ve seen games get remastered for a whole new generation of console hardware in less time. But Sega’s ...
Takeda is hoping to get a grasp on some of the PsA market which GlobalData forecasts will be worth $11.56bn in 2030. Credit: Michael Vi / Shutterstock.com Takeda’s oral tyrosine kinase 2 (TYK2) ...
Please provide your email address to receive an email when new articles are posted on . Ixekizumab plus tirzepatide improved skin clearance and body weight in people with difficult-to-treat psoriasis ...
ICOTYDE™ (icotrokinra) was approved by the US FDA in March 2026 for the treatment of moderate-to-severe PsO. ICOTYDE™ (icotrokinra) is the first and only targeted oral peptide approved for the ...
What is known about the total number of players? In March 2026, those responsible at SEGA announced on pso2.com that the PSO2 series has welcomed 12 million players worldwide on the servers. To ...
Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES PUBLIC NOTICES OBITUARIES JOBS CLASSIFIEDS EVENTS PETS CONTACT US ADVERTISING CULTURE & CAREERS ...
Hosted on MSN
A drug combo that includes a GLP-1 may improve psoriasis and psoriatic arthritis symptoms
In clinical trials involving people with psoriasis or psoriatic arthritis who were overweight or had obesity, those who took the biologic drug Taltz plus the GLP-1 drug Zepbound had better results ...
Ixekizumab and tirzepatide administered concomitantly was superior to ixekizumab alone in achieving complete skin clearance and at least a 10% weight reduction. The concomitant use of ixekizumab and ...
Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with plaque psoriasis and obesity or ...
The results from two recent clinical trials reinforce that treating obesity alongside inflammation can improve quality of life for many people with psoriatic diseases. In clinical trials involving ...
With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. Chalk up another new potential expansion for Lilly as it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results